Spinal Cord Stimulation Segment, by Treatment, to Dominate Brain Implants Market During 2022–2030 

According to our new research study on "Brain Implants Market Size and Forecast (2020–2030), Global and Regional Share, Trends, and Growth Opportunity Analysis," the brain implants market size is expected to grow from US$ 7,205.80 million in 2022 and to reach a value of US$ 17,647.65 million by 2030; it is anticipated to record a CAGR of 11.8% from 2022 to 2030.

Brain implants offer potential therapeutic solutions by modifying neural activity and restoring normal brain function. In addition, people have become more aware of the advantages of brain implants, and positive research outcomes are favoring brain implants market growth. Growing reliance on deep brain stimulation as a safe and proven treatment for Parkinson's creates growth opportunities for the brain implants market. The industry is expected to experience further growth in the coming years as more and more neural implants are being used to help with memory, disease treatment, and prosthetic limb communication to effectively reduce the symptoms of brain-related disorders.
 
The brain implants market, by treatment, is segmented into deep brain stimulation, spinal cord stimulator, vagus nerve stimulator, invasive and non-invasive brain–computer interfaces, responsive neurostimulation for seizures, auditory brainstem implant, and ophthalmic aids/implant. The spinal cord stimulator segment held the largest share of the market in 2022. However, the invasive and non-invasive brain–computer interfaces segment is estimated to register the highest CAGR in the market during 2022–2030. Spinal cord stimulation (SCS) can help manage chronic pain when the cause cannot be entirely treated using conventional methods, or the injury cannot be repaired. This therapy offers relief and improves the daily functioning of patients suffering from chronic pain. It is indicated for the management of chronic, intractable pain of the trunk, including unilateral or bilateral pain. Furthermore, SCS helps in targeted pain relief. SCS devices are available in different varieties that can be used as an alternative to other sorts of treatments, such as opioids, to which patients can develop addiction.

Based on application, the brain implants market is segmented into chronic pain, Parkinson’s disease, Alzheimer’s disease, epilepsy, essential tremor, depression, dystonia, amyotrophic lateral sclerosis/stroke/spinal cord injury, and neurofibromatosis 2/total ossification of the cochlea. The chronic pain segment held the largest market share in 2022. However, the Alzheimer’s disease segment is projected to register the highest CAGR during 2022–2030. Chronic pain refers to persistent or recurring pain that persists beyond the average healing time of an injury or illness, usually persisting for more than 3–6 months. It can result from various underlying conditions and can affect any part of the body. Chronic pain is a complex and multifaceted condition that can significantly impact a person's physical and emotional well-being, quality of life, and daily functioning.

Managing chronic pain can be challenging as it often involves a combination of treatments—including medication, physical therapy, lifestyle changes, and psychological interventions. According to UCSF estimates, 1 in 4 persons in the US were experiencing chronic pain in 2020, and many of them were resistant to therapy. People who have pain from spinal injuries, post-stroke pain, phantom limb pain, nerve pain, and other illnesses frequently experience misery without much hope for treatment.

Based on end-user, the brain implants market is bifurcated into hospitals and specialized clinics/neurological centers. The hospitals segment held a larger market share in 2022 and is anticipated to grow at the fastest rate during 2022–2030. Hospitals are complex organizations that provide healthcare services by using complicated but specialized scientific equipment. They employ teams of professionals trained to address the problems of modern medical sciences. They are all coordinated together for the common goal of restoring and maintaining good health. As specialized healthcare facilities, hospitals have key set-ups for the diagnosis, treatment, and management of various neurological conditions that may require brain implant interventions.

Hospitals provide pre-and post-operative care, which includes the assessment and selection of suitable candidates for brain implants. They also provide continuous monitoring and programming and schedule follow-up visits to ensure the proper functioning of these implants, eventually optimizing outcomes for patients undergoing implantation procedures. Hospitals serve as centers of expertise, housing multidisciplinary teams of neurologists, neurosurgeons, nurses, and other healthcare professionals who collaborate to provide specialized care for patients receiving brain implants. 

Boston Scientific Corp, Medtronic Plc, Functional Neuromodulation Ltd, Fisher Wallace Laboratories Inc., Synchron Inc., Blackrock Microsystems Inc, Renishaw Plc., Abbott Laboratories, Neurospine LLC, CorTec GmbH, BrainGate, Aleva Neurotherapeutics SA, NeuroSky Inc, Neuralink Corp, NeuroPace Inc., ONWARD Medical NV, and Paradromics Inc. are a few key companies operating in the brain implants market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name in the brain implants market.

Companies operating in the brain implants market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies in the brain implants market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall brain implants market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
 
A few of the significant developments by key market players are listed below.

•    In June 2023, Boston Scientific Corp received US Food and Drug Administration (FDA) approval for the Vercise Neural Navigator 5 Software, which when used as part of the Vercise Genus Deep Brain Stimulation (DBS) Systems. It provides clinicians with simple and actionable data for efficient programming in the treatment of people living with Parkinson’s disease or essential tremor. 
• In December 2022, Abbott launched the Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable SCS system available on the market for the treatment of chronic pain. The company’s portfolio of neuromodulation devices also includes Proclaim XR, the recharge-free SCS system, and Proclaim Plus featuring FlexBurst360.
•  In May 2022, Blackrock Neurotech collaborated with AE Studio, a group of world-class data scientists, developers, and designers who specialize in launching products that increase human agency. AE Studio bring passion for BCI to the MoveAgain program at Blackrock, which seeks to improve the lives of patients with paralysis and will contribute to expanding on Blackrock’s patented MoveAgain BCI system with a focus on user-friendly interfaces for clinicians and care team members.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com